

AAI - ASSESSORIA DE ASSUNTOS INTERNACIONAIS

De: Yoshinobu Nagamine <ynagamine@gavi.org>
Enviado em: sexta-feira, 26 de fevereiro de 2021 06:46
Para: Flavio Werneck Noce Dos Santos; Flavio Werneck; Arnaldo Correia de Medeiros; AAI - ASSESSORIA DE ASSUNTOS INTERNACIONAIS; Arnaldo Correia de Medeiros
Cc: Flavio Werneck Noce Dos Santos; Cristina Vieira Machado Alexandre; maria.azevedo@delbrasgen.org; victor.cirne@itamaraty.gov.br; nilo.dytz@itamaraty.gov.br; ambasad.delbrasgen@itamaraty.gov.br; edna.cesetti@presidencia.gov.br; dcid@itamaraty.gov.br; matheus.carvalho_itamaraty.gov.br; geral@paho.org; grosssoc@paho.org; perciojad@paho.org; procurement_coordinator@unicef.org; Li Zhang; Daniel Thornton; COVAX Facility; Juliette Marechal (Consultant)
Assunto: COVAX_Allocation for Brazil
Anexos: COVAX_SFP_AZ_Allocation_Brazil.pdf; Annex A_First round AZ allocation_AZ_SFP.pdf; SCHEDULE 4_Optional P_Form of Commitment Satisfaction Certificate.docx

Dear Honourable Minister of Health,

As you know, on 15th February, the WHO granted Emergency Use Listing (EUL) for the AstraZeneca vaccine. We are therefore pleased to confirm that this vaccine is officially authorised for use in Brazil within the framework of the COVAX Facility.

In light of this, we are sharing with you a letter detailing Brazil's final allocation of the AstraZeneca vaccine through May. The letter also includes the following key information:

- Next steps that you must ensure for Brazil to successfully access allocated doses
- An update on Pfizer Q2 supply

You will find attached to this letter an annex summarizing the key details of this first allocation round including additional information on the allocation process, the procurement process, the prerequisite steps for Brazil to complete in order to enable the receipt of doses, as well as a preliminary timeline for delivery.

Novavax Window 1

Following the Memorandum of understanding signed with [NOVAVAX](#), we will be opening the window 1 for this candidate later today, the window will remain open until March 12 2021. I will follow up with a separate email including the information pack and next steps.

Thank you for your continued engagement with the Facility. If you require any further clarifications, do not hesitate to contact me.

Kind regards,

Yoshi Nagamine

Yoshinobu Nagamine

Senior Manager, Resource Mobilisation & Private Sector Partnership
for Strategic Innovation and New Investors Hub

Tel: + 41 79 670 4616

Email: ynagamine@gavi.org

Global Health Campus
Chemin du Pommier 40
1218 Le Grand-Saconnex
Geneva, Switzerland
Tel: + 41 22 909 65 00
Web: <http://www.gavi.org>



NOTICE: This email, including any attachments to it, may be confidential and does not create any binding contract on behalf of Gavi or its partners.
If this email was sent to you in error, please notify the sender immediately by reply e-mail, and please do not use, distribute, retain, print or copy the e-mail or any attachment.

IMPORTANTE: FORAM IDENTIFICADOS LINKS NESTA MENSAGEM PARA ACESSO A SITES EXTERNOS, CUJA SEGURANÇA NÃO PÔDE SER VERIFICADA. É DE FUNDAMENTAL IMPORTÂNCIA COMPORTAR-SE DE MANEIRA SEGURA EM NOSSA REDE, NÃO ABRINDO ANEXOS E LINKS DESCONHECIDOS, AINDA QUE SUPOSTAMENTE ENVIADOS POR PESSOAS CONHECIDAS. LEMBRANDO QUE INSTITUIÇÕES FINANCEIRAS, DO PODER JUDICIÁRIO, SERVIÇO DE PROTEÇÃO AO CRÉDITO, NÃO ENVIAM E-MAILS COM AVISOS DE DÉBITOS, PROCESSOS E RECADASTRAMENTOS.

EM CASO DE DÚVIDA, CONTATE A CENTRAL DE ATENDIMENTO AO USUÁRIO.

ADMINISTRAÇÃO DA REDE MSNET
